Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-01-19
2009-11-17
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
07619058
ABSTRACT:
A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
REFERENCES:
patent: 6417165 (2002-07-01), Valmori et al.
patent: 6664232 (2003-12-01), Itoh et al.
patent: 2002/0039583 (2002-04-01), Subjeck et al.
patent: 2003/0148463 (2003-08-01), Kufer et al.
patent: 2 325345 (1999-10-01), None
patent: 8-500103 (1996-01-01), None
patent: 11-318455 (1999-11-01), None
patent: 2000-116383 (2000-04-01), None
patent: 2001-245675 (2001-09-01), None
patent: 2002-510496 (2002-04-01), None
patent: 2003-270 (2003-01-01), None
patent: 2003-510334 (2003-03-01), None
patent: 2003-533175 (2003-11-01), None
patent: 94/03435 (1994-02-01), None
patent: 97/15597 (1997-05-01), None
patent: WO 97/15597 (1997-05-01), None
patent: 00/06595 (2000-02-01), None
patent: 01/23421 (2001-04-01), None
patent: 01/36453 (2001-05-01), None
patent: 03/012086 (2003-02-01), None
patent: WO 03/012086 (2003-02-01), None
K.C. Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptie side-chains”, J. Immnol., vol. 152, pp. 163-175, (1974).
K.C. Parker, et al., “Scheme for ranking potential HLA-A2 binding peptides based on Independent binding of individual peptide side-chains”, Journal of Immunology, 1994, 152: 163-175.
K. Tajima et al., “Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted-cytotoxic T-lymphocyte response”, Tissue Antigens, 2004, 64:650-659.
G.V. Ullenhag et al., “Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response”, Clin. Cancer Res., 2003, 9(7):2447-2456.
Australian Office Action dated Oct. 5, 2007.
Australian Search Report 2005.
European Office Action dated Dec. 6, 2007.
Victor H. Englehard “Structure of Peptides Associated with Class I & II MHC Molecules”, Annual Review of Immunology (1994), pp. 181-207.
Andreas Trojan et al., “Generation of Cytotoxic T Lymphocytes against Native and Altered Peptides of Human Leukocyte Antigen-A*0201 Restricted Epitopes from the Human Epithelial Cell Adhesion Molecule”, Cancer Research (2001), pp. 4761-4765, vol. 61.
Elisabeth Ras et al., “Identification of Potential HLA-A *0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Anitgen (CEA)” American Society for Histocompatibility & Immunogenetics (1997), pp. 81-89, vol. 53.
Aichi Prefecture
Otsuka Pharmaceutical Co.
Sughrue & Mion, PLLC
Yu Misook
LandOfFree
Epitope/peptide recognized by HLA-A2402-restricted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epitope/peptide recognized by HLA-A2402-restricted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epitope/peptide recognized by HLA-A2402-restricted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094766